STAMFORD, Conn., Feb. 20 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. announced today that it will host a conference call after the close of market trading on March 1, 2007 to discuss recent corporate developments and select financial results for the year ended December 31, 2006. A question and answer session will immediately follow management’s prepared remarks.
Richard Taney, Chief Executive Officer, Dr. Samuel Herschkowitz, Chief Operating Officer, and Dr. Seymour Fein, Chief Scientific Officer, will host the conference call at 4:15 p.m. ET. The dial-in number for callers to participate is 973-582-2770, access code 8466047.
A replay of the call will be available through March 8, 2007. To access the replay, please dial 973-341-3080, and then enter the access code 8466047.
A live webcast of the call will be available at www.kcsa.com and on the Company’s website at www.delcath.com. All webcast participants are instructed to log into the webcast approximately 20 minutes prior to the call to download the necessary software plug-ins. The webcast will be archived on Delcath’s website for 30 days following the conclusion of the call.
About Delcath Systems, Inc.
Delcath Systems is a developer of percutaneous isolated perfusion technology for organ or region-specific delivery of therapeutic agents. The Company’s intellectual property portfolio currently consists of 12 patents on a worldwide basis, including the United States, Europe, Asia and Canada. For more information, please visit the Company’s website, www.delcath.com.
This release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
Company Contact: Investor Contacts: Delcath Systems, Inc. Todd Fromer / Garth Russell Richard Taney KCSA Worldwide 203-323-8668 (212) 896-1215 / (212) 896-1250 www.delcath.comtfromer@kcsa.com / grussell@kcsa.com Media Contact: Lewis Goldberg KCSA Worldwide (212) 896-1216 lgoldberg@kcsa.com
Delcath Systems, Inc.
CONTACT: Richard Taney, +1-203-323-8668, of Delcath Systems, Inc.; orMedia, Lewis Goldberg, +1-212-896-1216, lgoldberg@kcsa.com, or InvestorContacts, Todd Fromer, +1-212-896-1215, tfromer@kcsa.com, or Garth Russell,+1-212-896-1250, grussell@kcsa.com, all of KCSA Worldwide for Delcath
Web site: http://www.delcath.com/
